What is Nuvation Bio's AFS securities?

Nuvation Bio (NUVB) reported AFS securities of $365.13M in Q4 2025.

How has Nuvation Bio's AFS securities changed year-over-year?

Nuvation Bio's AFS securities decreased by 21.8% year-over-year, from $466.97M to $365.13M.

What is the long-term trend for Nuvation Bio's AFS securities?

Over 4 years (2021 to 2025), Nuvation Bio's AFS securities has grown at a -12.3% compound annual growth rate (CAGR), from $618.17M to $365.13M.

What does AFS securities mean?

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

Nuvation Bio NUVB AFS Securities

AFS Securities at other companies

Arcus BiosciencesRCUS

$54M+575%

Nektar TherapeuticsNKTR

$162.99M+7,973%

Crinetics PharmaceuticalsCRNX

$458.19M—

Summit TherapeuticsSMMT

——

IncyteINCY

——

Other financials

Income statement

See full

Revenue$83.2M+2,599%

Gross profit$9.8M+1,340%

Operating income$3.9M+107%

Net income$5.4M+110%

EPS (diluted)$0.01+106%

Balance sheet

See full

Cash & equivalents$125.4M+161%

Total debt$57.2M+401%

Total equity$319.6M-23.8%

Total assets$610.2M+23.9%

Cash flow

See full

Operating cash flow$5.1M+112%

CapEx$48.0K-33.3%

Free cash flow$5.0M+112%

Valuation

See full

Market cap$2.25B+150%

Profitability

See full

Gross margin54.3%+39.5pp

Operating margin-105%-52.0pp

Net margin-102.1%-50.6pp

FCF margin-93.5%-45.2pp

Returns & leverage

See full

Return on equity-39.5%-15.8pp

Debt / equity0.2×+0.2×

Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Nuvation Bio's AFS securities?: Nuvation Bio (NUVB) reported AFS securities of $365.13M in Q4 2025.
How has Nuvation Bio's AFS securities changed year-over-year?: Nuvation Bio's AFS securities decreased by 21.8% year-over-year, from $466.97M to $365.13M.
What is the long-term trend for Nuvation Bio's AFS securities?: Over 4 years (2021 to 2025), Nuvation Bio's AFS securities has grown at a -12.3% compound annual growth rate (CAGR), from $618.17M to $365.13M.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.